StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.41−0.03 (-2.08%)

Close on Nov 18, 2026Market cap $117.61MP/E –Yield –

Pyxis Oncology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Pyxis Oncology's revenue for the twelve months ending Dec 31, 2025 was $13.86M, down 14.2% year over year. For fiscal 2025 it was $13.86M, down 14.2% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.86M-14.2%
FY2024Dec 31, 2024$16.15M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$11.04M–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$2.82M-82.5%
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$16.15M–

More Pyxis Oncology figures

See a number that looks wrong?